Clinical trials: Oral Squamous Cell Carcinoma
Head and Neck Squamous Cell Cancer
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
This is an open label, single arm Phase II study of induction chemotherapy followed by concurrent chemo-radiotherapy in patients with locally advanced head and neck squamous cell cancer (HNSCC) using monoclonal antibody…
- Trial name
- NCT01326923
- Testing
- Cetuximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Head and Neck Cancer
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
RATIONALE: Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00079079
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma
Longitudinal Oral Health Changes After Head and Neck Radiotherapy
This prospective observational study evaluates how head and neck radiotherapy affects oral health over time. Patients with head and neck cancer undergoing standard radiotherapy are followed from before treatment through multiple…
- Conditions
- Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma, Periodontal Disease, Xerostomia
- Trial name
- HN-ORAL-RT (NCT07394842)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Oral Squamous Cell Carcinomas, Oral Potentially Malignant Disorder
Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma
The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients.
- Trial name
- HOPES (NCT07579507)
- Testing
- Biospecimen, Blood sampling
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Leon Berard
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III
- Trial name
- NCT03993353
- Testing
- Pembrolizumab, Tadalafil
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Low-grade Oral Dysplasia
Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia
There are limited evidence-based management options for patients with low-grade oral dysplasia. Despite the risk of malignant transformation, management is frequently limited to risk factor reduction (such as smoking cessation)…
- Trial name
- NCT05707702
- Testing
- Probiotic oral lozenges, Standard of care for oral dysplasia
- Where
- United States
- Sponsor
- Boston Medical Center
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
This phase II trial compares the effect of adding proton spatially fractionated radiotherapy (SFRT) or photon stereotactic body radiotherapy (SBRT) to standard immunotherapy pembrolizumab before surgery (neoadjuvant) in treating…
- Conditions
- Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT07783581
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Head and Neck Cancer
Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114153
- Testing
- capecitabine, carboplatin, conventional surgery
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Virginia
Head and Neck Cancer
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer
RATIONALE: Studying gene mutations in samples of DNA from patients with head and neck cancer and a family history of cancer may help doctors learn more about the development of cancer in families.
- Trial name
- NCT00482872
- Testing
- gene expression analysis, mutation analysis, polymerase chain reaction
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Vanderbilt University Medical Center
Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer
This trial is to determine what dose of a drug called AZD1775 can safely be given in combination with cisplatin before surgery and with chemo-radiotherapy after surgery in patients with Head and Neck Cancer.
- Conditions
- Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Larynx Cancer
- Trial name
- WISTERIA (NCT03028766)
- Testing
- AZD1775, Cisplatin, Radiotherapy
- Where
- 6 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- University of Birmingham
Oral Cancer
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer
The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients.
- Trial name
- HNC-SYSU-005 (NCT06143761)
- Testing
- PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This randomized phase II trial is studying bortezomib and irinotecan to see how well they work compared to bortezomib alone in treating patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00103259
- Testing
- bortezomib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002670
- Testing
- chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy
- Where
- 23 sites in United States, South Africa
- Volunteers
- 459 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer
Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may help prevent or treat cancer-related anemia.
- Trial name
- NCT00017277
- Testing
- epoetin alfa, radiation therapy
- Where
- 15 sites in Australia, Belgium and 8 more
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083057
- Testing
- gefitinib, paclitaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder
NBI for Early Diagnosis of OPMD/OSCC
Early detection - possibly at its pre-malignant stages (Oral Potentially Malignant Disorders, OPMD) - with periodic surveillance is thus fundamental for limiting disease burden, hopefully reducing the incidence of advanced stages…
- Trial name
- NBI_Oral (NCT06438939)
- Testing
- Biopsy for diagnostical purposes
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- Cardarelli Hospital
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
This phase I trial studies the side effects of nivolumab and IRX-2 and how well they work in treating participants with stage III-IVA oral cavity cancer or human papillomavirus (HPV)-positive oropharyngeal cancer that can be…
- Conditions
- Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT03575234
- Testing
- Cyclophosphamide, IRX-2, Nivolumab
- Where
- 2 sites in United States
- Sponsor
- Emory University
Oral Squamous Cell Carcinoma
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
The research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (COX-2) inhibitor…
- Trial name
- NCT02739204
- Testing
- Celecoxib
- Where
- Taiwan
- Volunteers
- 270 people
- Sponsor
- China Medical University Hospital
Head and Neck Cancer, Lung Cancer
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of zileuton may be an effective way to prevent lung cancer in patients who have bronchial…
- Trial name
- NCT00056004
- Testing
- zileuton
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute